News

Through the investment, Evotec which calls itself as a drug discovery alliance and development partnership company has become the first strategic shareholder in Exscientia. Evotec with over 1,800

“This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop therapy resistance strategies,” said Aung Naing, M.D., associate professor of Investigational

The New York-based biopharmaceutical company said that the preliminary results were observed from the first six subjects enrolled in the open-label trial dubbed NCT02226146. Immune Pharmaceuticals stated that

Jacobs was selected for this project phase following the successful completion of the conceptual study and basic engineering design As Ferring Pharmaceuticals’ principal biopharmaceutical product development center, this

Bevespi Aerosphere showed a significant improvement in lung function as measured by trough forced expiratory volume in one second (FEV1), compared to its monotherapy components (glycopyrronium 14.4 µg

New investors Cormorant Asset Management, Nextech Invest and others joined founding investor Syncona Ltd, Woodford Investment Management and Arix Bioscience in this Series C round. The funds will

The phase 3 clinical trial dubbed as MINDSET featured 1,315 patients with mild to moderate Alzheimer's disease who were on donepezil therapy over 24 weeks. Intepirdine taken orally

The primary objective for this randomized placebo-controlled, Phase 2 study is to evaluate the efficacy and safety of the immuno-oncology-based combination compared to gemcitabine/ABRAXANE alone. Patients will also

 The complete response letter indicates additional clinical data are needed to further evaluate the safety of sirukumab in the treatment of moderately to severely active RA. "We are